-
Rewrite The APPLE’s core question—upfront osimertinib versus the sequential approach for EGFR mutated non-small cell lung cancer this news headline for the science magazine post
06 May 2025 19:42 GMT
… small-cell lung cancer (NSCLC): EORTC Lung Cancer Group … Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer … versus Caucasian lung cancer patientsbrain metastasis control … -small cell lung cancer trialsosimertinib treatment …
-
Innovent Announces NMPA Approval Of Limertinib, A Third-Generation EGFR TKI Collaborated With ASK Pharma, For The First-Line Treatment Of Lung Cancer
26 Apr 2025 02:14 GMT
… receive either limertinib or gefitinib. The primary endpoint … of precision therapies for lung cancer-including limertinib, Retsevmo®( … non-small-cell lung cancer (NSCLC)
Lung cancer remains one of … mutated non-small cell lung cancer (NSCLC), who have …
-
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study
21 Apr 2025 12:39 GMT
… and correlates of lung cancer recurrence. Clin Lung Cancer. 2020;21(2 … in lung cancer: correlation with clinical response to gefitinib therapy. … Non-Small Cell Lung Cancers in a Multiethnic … With Clinicopathological Characters of Lung Cancer Patients. World J …
-
Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China
14 Apr 2025 14:59 GMT
… lung cancer cases and 766,898 lung cancer- … lung cancer (NSCLC) accounts for the majority (80% - 85%) of all lung cancers … Cost-effectiveness of gefitinib, icotinib, and pemetrexed … lung cancer: a cost-effectiveness analysis. Translational Lung Cancer …
-
EU approves AstraZeneca's Imfinzi─in combo with chemotherapy to treat patients with resectable non─small cell lung cancer
05 Apr 2025 07:44 GMT
… Lung cancer is broadly split into NSCLC and small cell lung cancer … portfolio includes leading lung cancer medicines and the … (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu … improvements for people with lung cancer, including and beyond …
-
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
25 Mar 2025 23:28 GMT
… Lung cancer is broadly split into small cell lung cancer … of Lung Cancer 2022 World Conference on Lung Cancer (WCLC … lung cancer medicines and the next wave of innovations, including TAGRISSO and gefitinib … for people with lung cancer, including and beyond …
-
Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study
19 Mar 2025 11:09 GMT
… of oncogenic drivers in lung cancers to select targeted drugs … advanced non-small cell lung cancer: a retrospective multicenter study … non-small cell lung cancer. Transl Lung Cancer Res. 2024;13 … mutations who receive gefitinib. Clin Lung Cancer. 2013;14(4 …
-
Vokes Explores Biomarker Testing and Treatment Landscape for EGFR-Mutated Lung Cancer
18 Mar 2025 17:02 GMT
… patients with non–small cell lung cancer (NSCLC)?
VOKES: The … In] patients with metastatic lung cancer who have a targetable driver … then we switched to gefitinib [Iressa] because there were … of Lung Cancer global survey on molecular testing in lung cancer. J …
-
EU approves AstraZeneca's Imfinzi as monotherapy to treat adults with limited─stage small cell lung cancer
18 Mar 2025 13:14 GMT
… limited-stage small cell lung cancer (LS-SCLC) whose … portfolio includes leading lung cancer medicines and the … Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu … improvements for people with lung cancer, including and beyond treatment …
-
Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
11 Mar 2025 07:13 GMT
… lung cancer (NSCLC) is the predominant form of lung cancer, … representing approximately 85% of all lung cancer … in lung cancer: correlation with clinical response to gefitinib therapy … the lung cancer epidemic in China. Transl Lung Cancer Res. …
About
© 1995-2025